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Patients affected by psychotic disorders are more likely to develop high rates of
co-morbidities, such as obesity, type 2 diabetes, dyslipidemias, hypertension, metabolic
syndrome, myocardial infarction, stroke etc., in the long-term. These morbidities have
a significant impact on the life-expectancy of these patients. Patients with chronic
psychoses show a 2–3-fold increased risk of death mostly from cardiovascular
and metabolic diseases. Although there may be an independent link, between
schizophrenia and metabolic conditions the cardio-metabolic risk is mostly related
to an unhealthy lifestyle and the usage of antipsychotic agents (especially Second
Generation Antipsychotics or atypical) even when these remain effective treatments in
the management of major psychoses. Recently, many international organizations have
developed screening and monitoring guidelines for the control of modifiable risk factors
in order to reduce the rate of co-morbidity and mortality among patients affected by
schizophrenia. This paper is a review of current knowledge about the metabolic issues
of patients affected by schizophrenia and describes clinical characteristics and medical
management strategies for such conditions.
Keywords: diabetes, weight gain, metabolic syndrome, schizophrenia, psychosis, antipsychotics agents,
guidelines
Introduction
Patients diagnosed with psychotic disorders report a reduced expectancy of life and show higher
rate of physical co-morbidities said to be mostly due to an unhealthy life style and as a result of
treatment by antipsychotic drugs (Saha et al., 2007; Fleischhacker et al., 2008).
It has been described that patients affected by schizophrenia show a 2–3-fold increased risk
of death compared to the general population as a result of suicide and cardiovascular and
metabolic diseases (Saha et al., 2007; Fleischhacker et al., 2008). In 2004, the American Diabetes
Association (ADA) defined the Cardio-metabolic Risk (CMR) as a cluster of many risk factors
(ADA website1). Some of them are considered to be modifiable with dietary changes, physical
exercise (e.g., overweight/obesity, high blood glucose, hypertension, abnormal lipid metabolism,
physical inactivity, smoking) whereas others are seen as non-modifiable (e.g., age, race, ethnicity,
gender, family history). The prevalence and relative risk of modifiable factors are not only higher
1ADA Cardiometabolic Risk Initiative: http://professional.diabetes.org/resourcesforprofessionals.aspx?cid=60379 (accessed
02.08.2015).
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in the patients affected by psychotic conditions but such
individuals may also show relatively poor access to health care
system and higher levels of unhealthy lifestyle (Druss et al., 2001;
Cradock-O’Leary et al., 2002; Newcomer, 2005; Correll, 2007;
Fleischhacker et al., 2008).
Antipsychotic agents (APs) have been shown to greatly
influence those modifiable risk factors leading to weight gain
and metabolic changes among all patients treated (Newcomer,
2007; Nasrallah, 2008; Papanastasiou, 2013). In particular,
Metabolic Syndrome (constituting a cluster of clinical conditions
such as abdominal obesity, insulin resistance, dyslipidaemias,
hypertension) is well known to be highly prevalent among
individuals affected by psychosis. Metabolic syndrome is
also well recognized as being associated with an increased
cardiovascular risk and resulting mortality (Papanastasiou,
2013). Patients diagnosed with schizophrenia have been shown
to be overweight/obese (45–55%, RR: 1.5–2), smokers (50–80%,
RR: 2–3), to report diabetes (10–15%, RR: 2), hypertension (19–
58%, RR: 2–3), dyslipidemias (25–69% RR ≤ 5) and metabolic
syndrome (37–63%, RR: 2–3) (Correll, 2007). The median all-
causes standardized mortality ratio (SMR) for people affected by
schizophrenia has increased over the decades from 1.84 in the
1970s to 3.20 in 1990s (DeHert et al., 2009a). Also, cardiovascular
mortality in patients with schizophrenia also increased in
those decades especially among men (Osby et al., 2000). As
stated above, medical co-morbidities lead to a 20% shorter
lifespan among patients diagnosed with psychoses (Harris and
Barraclough, 1998; Castillo Sánchez et al., 2014; Ifteni et al., 2014;
McLean et al., 2014). In particular, schizophrenia is significantly
associated with premature mortality and a higher rate of sudden,
unexpected deathmostly as a result of cardiovascular, respiratory,
and neurological disorders (Ifteni et al., 2014). Early recognition
and treatment of such co-morbidities should, therefore, be a
priority for clinicians who treat patients with psychoses since
the standard risk assessment underestimates the risk of death
in schizophrenia (Harris and Barraclough, 1998; Ifteni et al.,
2014). Also, evidence from past few decades has confirmed that
there may be a link between major mental illness and metabolic
conditions without any influence of treatments since metabolic
disturbances have been found in drug-naïve patients with first-
episode illness (Ryan et al., 2003).
Genetic links between diabetes and schizophrenia were
recognized by Henry Maudsley in his 1897 textbook “The
Pathology of Mind” (Mausdley, 1897). Similarly, weight gain
and abnormal eating behaviors were recognized by Kraepelin
and Bleuler in the beginning of the twentieth century. These
observations have been recently confirmed in recent studies
showing that first- episode and drug naïve patients with
psychosis report impaired fasting glucose, insulin- resistance
and higher levels cortisol than healthy controls (Ryan et al.,
2003; Thakore, 2004). They also show higher rates of visceral
obesity related to a subtle disturbance of the hypothalamic-
pituitary-adrenal axis as alterations of hormonal and immune
pathways are recognized in the blood samples of patients
with schizophrenia (Thakore, 2004). Van Beveren et al. suggest
that the presence of a molecular endophenotype including the
disruption of insulin and growth factor also signals pathways
as a risk factor for schizophrenia (Phutane et al., 2011;
van Beveren et al., 2014). Moreover, drug naïve/first episode
schizophrenia patients present increased levels of IL-1β, IL-6,
and TNF-α and higher adiponectin levels that may play a pro-
inflammatory role leading to later metabolic syndrome (Song
et al., 2013).
Obviously, cardio-metabolic risk factors are lower among
drug-free/first episode patients than treated schizophrenia
patients, and the cardiovascular risk is not significantly higher
at this stage of illness. This indicates that first- episode patients
should be screened in order to put primary prevention of
cardiovascular morbidity and mortality in place (Phutane et al.,
2011; Mitchell et al., 2013).
The Role of Antipsychotic Agents
Psychopharmacological agents are effective and necessary for
the management and relapse- prevention of psychotic disorders:
untreated psychotic patients show much higher mortality and
suicide rates, more hospitalizations and worst outcomes of illness
with greater cognitive and functional impairment (Tiihonen
et al., 2006; De Hert et al., 2009a).
However, there is a considerable literature on the metabolic
adverse effects of antipsychotic agents and, in particular, Second
Generation Antipsychotics (SGAs) appear to induce more
weight gain and metabolic abnormalities than First Generation
Antipsychotics (FGAs) (Newcomer, 2007; Nasrallah, 2008; De
Hert et al., 2009a; Papanastasiou, 2013).
Clinicians employing newer antipsychotics deal with
metabolic side effects more frequently than extrapyramidal
symptoms and tardive dyskinesia. SGAs are responsible of new
cases of diabetes, probably due to specific diabetogenic actions, in
particular by drugs such as clozapine and olanzapine (Reynolds
and Kirk, 2010; Stahl, 2013). The diabetogenic mechanism may
involve a muscarinic M3- receptor antagonism (which is perhaps
more relevant for olanzapine and clozapine) since M3 receptors
are localized on beta- cells of pancreas and regulate the insulin
release and glucose levels homeostasis (Stahl, 2013). Also, M3-
receptors blockage might alter glucose metabolism leading to
diabetes, diabetic ketoacidosis, hyperosmolar syndrome, all
observed in patients treated with olanzapine and clozapine
(Reynolds and Kirk, 2010). Weight gain and dyslipidemias (in
particular hypertriglyceridemia) are also known to be trigger
factors for diabetes and are frequently induced by antipsychotics
like olanzapine and clozapine, whereas aripiprazole and
ziprasidone are associated with some weight- loss or poor
weight-gain (Reynolds and Kirk, 2010; Stahl, 2013; Table 1).
Weight gain might also be induced by 5HT2C- and H1- receptor
affinity of antipsychotic molecules: H1- receptors are localized
in the hunger and satiety centers held in the hypothalamus
and are responsible for hyperphagia (Reynolds and Kirk, 2010;
Stahl, 2013). Other receptor mechanisms may have additive
or synergistic effects. For example, dopamine D2 receptor
antagonism can enhance 5-HT2C-mediated effects on food
intake, as well as influencing lipid and glucose metabolism via
disinhibition of prolactin secretion (Reynolds and Kirk, 2010;
Stahl, 2013). SGAs also have an impact on the hypothalamic
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TABLE 1 | Side effects of SGAs (adapted from American Diabetes Association/American Psychiatric Association, 2004; De Nayer et al., 2005; Cohn and
Sernyak, 2006; De Hert et al., 2006; Tschoner et al., 2007; Leucht et al., 2009b).
Weight gain Dyslipidemia Diabetes EPS Prolactin increase Sedation QT- interval prolongation
Amisulpride + − + + +++ − −
Aripiprazole − − − +/− − + −
Asenapine +/− +/− − − − ++ −
Clozapine +++ ++ +++ − − +++ +
Olanzapine +++ ++ +++ − − +++ −
Quetiapine ++ + ++ − − ++ −
Risperidone ++ +/− ++ + +++ + ++
Ziprasidone +/− − − − + − ++
+++, high incidence;++, moderate incidence, +, low incidence, −, very low incidence; EPS, extra-pyramidal symptoms.
regions involved in the control of food-intake for example,
olanzapine increases NPY (neuropeptide Y) expression in the
ARC (Arcuate Nucleus) (Reynolds and Kirk, 2010; Stahl, 2013).
Between 15 and 72% of patients affected by psychotic
disorders report a significant weight gain during the acute
and maintenance treatment of their illness (De Hert et al.,
2009a). Studies have shown a significant 10-weeks weight gain
during the antipsychotic treatment which ranges widely with
different medications. For example, this weight gain for clozapine
is around (+4.45 kg) higher than that gained by olanzapine
(+4.15 kg) which is higher than quetiapine and risperidone
(+2.1 kg) which in turn are higher than those occurring as
result of treatment with aripiprazole and ziprasidone (<1 kg)
(Allison et al., 1999; De Hert et al., 2009a). These findings
have been confirmed by clinical trials such as CATIE (Clinical
Antipsychotic Trials of Intervention Effectiveness) and EUFEST
(European First Episode Schizophrenia Trial) Studies (Goff et al.,
2005; Lieberman et al., 2005; Daumit et al., 2008; De Hert et al.,
2009a; Leucht et al., 2009a).
Clinical factors associated with higher weight gain are younger
age, lower initial BMI, personal and family history of obesity,
non-white ethnic background, tendency to overeat in time of
stress, cannabis use and first episode psychosis (De Hert et al.,
2009a). Weight gain is not related to SGAs doses used, except for
olanzapine and clozapine (Simon et al., 2009).
There are some putative genes involved in the drug- induced
weight gain: the most replicated findings are regarding the genes
for melanocortin 4 receptor (MC4R), serotonin 2C receptor
(HTR2C), leptin, neuropeptide Y (NPY) and cannabinoid
receptor 1 (CNR1) (Shams and Müller, 2014).
Causality between antipsychotic usage and the onset of
diabetes can be difficult and as noted earlier, people with
psychotic disorders tend to show an increased risk for diabetes
even when drug- naïve or untreated (De Hert et al., 2009a).
Approximately 15% of patients with psychosis go on to
develop type 2 diabetes (Bushe and Holt, 2004). Since the
prevalence of diabetes among schizophrenia patients is higher
than in the general population (2-fold increased risk), in 2008
the Canadian Diabetes Association (CDA) defined schizophrenia
as an independent risk factor for type 2 diabetes including
the usage of second generation antipsychotics in the list of
risk factors (Canadian Diabetes Association Clinical Practice
Guidelines Expert Committee et al., 2013).
In addition, clozapine and olanzapine might influence insulin
secretion with a direct stimulating effect on pancreatic β-cells
(Melkersson et al., 2004). A significantly higher increase of
HbA1c levels with: olanzapine (0.4%) > quetiapine (0.04%) >
risperidone (0.07%) > perphenazine (0.09%) > ziprasidone
(0.11%) has been demonstrated thereby suggesting that not all
drugs are the same (Lieberman et al., 2005).
According to the evidence, a baseline assessment of fasting-
glucose is relevant in order to screen new cases of diabetes
developing as a result of antipsychotic treatments. Clinicians
managing patients affected by chronic psychoses need to make
better and more focused efforts to prevent diabetes and respond
to it early when it does occur (Ventriglio et al., 2014).
Coronary Artery Disease (CAD) includes the increase of low-
density lipoprotein cholesterol (LDL-C) and/or decrease of high-
density lipoprotein cholesterol (HDL-C). Studies have shown that
the usage of antipsychotic drugs is associated with an increase of
LDL-C and a decrease of HDL-C (Goff et al., 2005; Daumit et al.,
2008). The increase of LDL cholesterol may differ depending on
which anti-psychotic drugs are used. As seen before, clozapine
and olanzapine are two compounds which are associated with the
higher increase LDL and triglycerides in serum (Goff et al., 2005;
Daumit et al., 2008). It is important that the clinicians respond
rapidly in the early phase of treatment when weight gain is most
likely to occur (Goff et al., 2005; Daumit et al., 2008). It has been
recommended that clinicians should measure lipid levels every
2–3 months following the commencement of treatment and also
once weight- gain has reached stable levels (De Hert et al., 2009a).
Lipid concentration can be reduced rapidly following a psycho—
educational and monitoring program focused on diet, physical
exercise and better life- style (Ventriglio et al., 2014).
Increase in levels of blood pressure may occur sporadically,
mostly during the clozapine treatment (Gardner and Teehan,
2011). In contrast, reduction of blood pressure with associated
symptoms of feeling weak is a common occurrence with many
antipsychotic treatments. Syncopal episodes related to orthostasis
may happen, mostly due to low-potency first-generation
antipsychotics (α1-Adrenergic and calcium—receptors blockage
is generally involved in this adverse effect). Posture-related drops
in blood pressure are especially common with first-generation
antipsychotics. A slower dosage titration has been recommended
and with most drugs, tolerance develops with continued use, and
these effects appear to recede (Gardner and Teehan, 2011).
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Metabolic Syndrome and Psychosis
The Metabolic Syndrome (MetS; also known as Syndrome X or
Reaven’s syndrome) constitutes of a cluster of different clinical
conditions, including abdominal obesity, insulin resistance,
dyslipidaemias, and elevated blood pressure. All components of
the MetS have been recognized as independent risk factors for
cardiovascular disease, pro-thrombotic state, pro-inflammatory
state, non-alcoholic fatty liver disease and reproductive disorders
(Papanastasiou, 2013).
Criteria for definition of MetS have developed over the
decades as more information has emerged. World Health
Organization (WHO) produced the definitions in 1985,
European Group for the Study of Insulin Resistance in 1999,
National Cholesterol Education Program’s Adult Treatment
Panel III (NCEP-ATP III) in 2001 (modified in 2003), American
Association of Clinical Endocrinologists in 2003 and finally
by the International Diabetes Federation (IDF) in 2006
(Papanastasiou, 2013).
MetS is diagnosed when 3 out of the following 5 criteria are
recognized in the same patients:
(1) Increased waist circumference,M > 102 cm/F > 88 cm
(IDF:M ≥ 94 cm/F ≥ 80 cm);
(2) Elevated triglycerides (≥150mg/dl) or drug treatment for
dyslipidaemia;
(3) Reduced high-density lipoprotein (HDL) (<40mg/dl) or
being on drug treatment for hypercholesterolaemia;
(4) Elevated blood pressure (systolic ≥ 130mmHg, diastolic ≥
85mmHg) or a history of hypertension or drug treatment for
hypertension;
(5) Elevated levels of fasting glucose (≥100mg/dl) or being on
medication treatment for hyperglycaemia.
Papanastasiou (2013) observed that the prevalence rates of MetS
vary across samples reported depending upon the variety of
patients, their age, sex, ethnicity, medication status, smoking,
duration, and outcomes of illness. Generally, the prevalence rates
of MetS vary from 3.9 to 68%, including patients treated with
FGAs and/or SGAs. It has been noted that of the prevalence of
MetS peaks in the fourth/fifth decade of life. Again, clozapine
and olanzapine appeared to be related to higher rates of MetS
compared with other antipsychotic agents (Centorrino et al.,
2012). Also, the comparisons between previously unmedicated
and currently treated patients show an increase in prevalence
from 24.7 to 49.6% of MetS. Not surprisingly, patients treated
with SGAs show much higher rates of MetS compared to those
treated with FGAs (27.8 vs. 9.8%) (De Hert et al., 2009b;
Papanastasiou, 2013).
Recently it has been reported that MetS may influence
the cognitive functioning in patients with chronic psychosis–
especially in immediate memory, delayed memory, and attention
(Li et al., 2014).
Prolactin Levels
Hyperprolactinemia induced by antipsychotic medication is
mostly due to D2-receptors blockade in the tubero-infundibular
dopaminergic system of the hypothalamus. The magnitude
of hyperprolactinemia correlates strongly with dopamine D2
receptor blockade- potency of the medication being taken.
Prolactin levels may produce clinical signs and consequences:
galactorrhea, gynecomastia, oligomenorrhea, amenorrhea,
reduced libido, dyspareunia, vaginal dryness for women; reduced
libido, erectile dysfunction, ejaculatory dysfunction for men
(Gardner and Teehan, 2011; Li et al., 2014). Osteoporosis,
hypogonadism, and breast cancer have been associated with
prolactinomas, in which prolactin levels can exceed 5000 ng/ml
(Gardner and Teehan, 2011; Li et al., 2014). It has been
recommended that, prolactin should be measured at baseline
and over the follow-up period (monitoring hyperprolactinemia-
related signs and symptoms) (Ventriglio et al., 2014). Prolactin
levels range from 0 to 20 ng/ml (0–424 mIU/l) in non-pregnant
women: whereas levels for pregnant women are lower than
200 ng/ml (≤ 4240mIU/l). For men the levels should range
from: 0 to 15 ng/ml (0–318 mIU/l) (Kratz et al., 2004).
Hyperprolactinemia occurs more frequently in females than
males, despite lower doses used in women. Return to normal
prolactin levels occurs rapidly upon discontinuation of treatment
(Halbreich et al., 2003; Gardner and Teehan, 2011).
Hyperprolactinemia associated with antipsychotic
medication has been observed with effects from risperidone
= paliperidone = amisulpride = haloperidol (at 74–91%)
which is greater than that for olanzapine (2–20%) which is
higher than that related to quetipaine (not significant increase)
which is higher than that for aripiprazole = ziprasidone (not
significant increase) (Halbreich et al., 2003; Gardner and Teehan,
2011).
When prolactin levels are high, but lower than 150 ng/ml,
clinician must consider a switch from the current antipsychotic
to another which is not associated with a significant increase in
prolactin levels while taking into account the risk of rebound
in psychotic symptoms. They may consider introducing a
dopamine agonist like cabergoline, bromocriptin, pergolide.
If prolactin levels are higher than 150 ng/ml, then advice
from an endocrinologist may help along with neuro-imaging
investigations to exclude pituitary and juxtasellar adenomas (De
Hert et al., 2014).
QT- interval Prolongation
Using electro-cardiogram the functioning of the heart is assessed
and in this context, QT interval is a measure of the time between
the start of the Q wave and the end of the T wave in the
heart’s electrical cycle. In general, the QT interval represents
electrical depolarization (Na+ and Ca++ intake in the cells) and
repolarization (K+ output) of the ventricles. QT is corrected for
heart rate (QTc) derived from the heart rate (HR) as 60 beats per
minute according to Bazzett’s formula.
Although QT may vary according to age, sex, circadian
rhythms; a lengthened QT interval is a marker for the potential
of ventricular tachyarrhythmias like torsades de pointes and a
risk factor for sudden death. A QTc value above 500ms or an
increase of 60ms (20% from baseline) is strongly associated with
arrhythmias and torsade de pointes (TdP).
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Antipsychotic agents may prolong QTc interval depending on
their binding- potency to IKr channels of ventricle repolarization
(HERG channels). Second generation antipsychotic mostly
involved with QTc- prolongation are ziprasidone, risperidone,
paliperidone, clozapine, quetiapine. aripiprazole, olanzapine, and
asenapine are associate with lower variations in QTc- interval
(Gardner and Teehan, 2011; Hasnain and Vieweg, 2014).
First generation antipsychotics are responsible for a higher
QTc- prolongations, in particular drugs like haloperidol.
Thioridazine, sertindole have consequently been withdrawn
worldwide since these drugs lead to arrhythmias and sudden
death. There is no doubt that good clinical practice demands
that antipsychotic should be prescribed with caution for
patients affected by cardiovascular diseases (congenital long QT
syndrome, myocardial infarction, cardiac failure, arrhythmias) or
other risky conditions (previous TdP or hypokalaemia) (Gardner
and Teehan, 2011; Hasnain and Vieweg, 2014).
Finally, it has been reported that myocarditis may occur
during the treatment with clozapine, in particular in the first 2
months of it (in up to 85% of cases). Also, patients treated with
chlorpromazine or fluphenazine may develop myocarditis. If
clinical signs of myocarditis are suspected (e.g., tachycardia),
the drug should be stopped immediately (Gardner and Teehan,
2011).
Monitoring Metabolic Disorders among
Patients Affected by Chronic Psychosis
There have been many attempts by several international societies
to develop guidelines for screening and monitoring metabolic
consequences of psychosis and antipsychotic treatments. The
aim of such procedures is to reduce those modifiable factors
associated to the risk of cardiometabolic conditions among
patients affected by schizophrenia (De Hert et al., 2009a).
Guidelines developed by the European Psychiatric Association
(EPA), supported by the European Association for the Study
of Diabetes (EASD) and the European Society of Cardiology
(ESC), also known as EPA/EASD/ESC Position Statement
are very helpful in clinical settings (De Hert et al., 2009a;
Table 2).
For a number of reasons, these recommendations have been
poorly followed and employed in the clinical settings. It is well
known that when applied, these guidelines appear to improve
the metabolic outcome of patients affected by schizophrenia and
bipolar disorders (De Hert et al., 2009a, 2011; Ventriglio et al.,
2014).
The baseline examination of patients should include
history of previous cardiovascular diseases, diabetes or other
related disease; family history of premature CVD, diabetes
or other related disease; smoking habits, food selection,
physical activity; weight and height in order to calculate
body mass index (BMI) and waist circumference; fasting
blood glucose levels; fasting blood lipids: total cholesterol,
triglycerides, LDL cholesterol (by calculation) and HDL-C;
blood pressure (measured twice and average taken), heart rate,
heart and lung auscultation, foot pulses; ECG (De Hert et al.,
2009a).
If metabolic parameters are within the normal range in
patients on antipsychotic treatment for more than 12 months,
it is recommended that clinicians must repeat previous factors
annually. If values are in normal ranges at baseline in drug-
naïve patients, monitoring has to be repeated at week 6, 12, and
annually (paying particular attention to weight gain within the 6
week of treatment) (De Hert et al., 2009a).
TABLE 2 | EPA/EASD/ESC Position Statement (adapted from De Hert et al., 2009a).
Baseline AP Prescription W 1 W 2 W 3 W 4 W5 W6 W12 M6 M9 1 year
Weight X X X X X X X X X X X
Height X
BMI X X X
Waist circ. X X
FBG X X X X X
TC X X X X X
TG X X X X X
LDL-C X X X X X
HDL-C X X X X X
HbA1c X X X X X
Blood pressure X X X
HR X
Chest auscul. X
Pulse X
ECG§ X
Other* X X
Circ., circumference; auscul., auscultation. If patient is suffering from diabetes, HbA1c should be measured 3-monthly. Urinary albumin, creatinine, ophtalmology visit, and feet check-
up should be planned annually.
BMI, body mass index; FBG, fasting blood glucose; TC, total cholesterol; TG, triglycerides; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol;
HbA1c, glycated hemoglobin; HR, heart rate; ECG, Electrocardiography.
§ECG should be repeated yearly and in case of drug and dose changes.
*Any other medical assessment, if needed; W, week; M, month.
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In presence of one or more risk factors, the antipsychotic
treatment must be selected carefully, matching the efficacy
and safety (metabolic) perspective. Specific treatments
may be required to reduce the cardiovascular risk.
Clinicians have to involve general practitioners in order to
collaborate with them in managing the risk factors. EPA
guidelines recommend that BMI should be ≤25 kg/m2, waist
circumference <102 cm (men)/<88 cm (women), blood
pressure ≤140/90mmHg—triglycerides < 190mg/dL—LDL
< 115mg/dL in non-diabetic patients. The, glycosylated
hemoglobin < 7%—blood pressure ≤ 130/80mmHg—
triglycerides <175mg/dL—LDL < 100mg/dL should be
the recommended levels in patients with diabetes. Patients
with diabetes should have their glycosylated hemoglobin levels
measured 3-monthly and microalbuminuria, renal functioning,
ophtalmological and feet examination yearly (De Hert et al.,
2009a).
Conclusions
Metabolic consequences of treatment with antipsychotic
medication increase the risk of mortality among patients
affected by chronic psychosis and many of the factors are
preventable. Patients with psychoses appear to show higher
levels of cardiometabolic co-morbidites in comparison with
general population and 2–3-fold increased risk of premature
death. Clinicians need to employ international guidelines and
procedures to screen and monitor these co-morbid conditions
in order to reduce mortality rates among patients affected
by psychotic disorders and improve the outcome of illness,
including patients’ global functioning and quality of life.
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